JP6092897B2 - 脊髄性筋萎縮症を治療するための化合物 - Google Patents
脊髄性筋萎縮症を治療するための化合物 Download PDFInfo
- Publication number
- JP6092897B2 JP6092897B2 JP2014556711A JP2014556711A JP6092897B2 JP 6092897 B2 JP6092897 B2 JP 6092897B2 JP 2014556711 A JP2014556711 A JP 2014556711A JP 2014556711 A JP2014556711 A JP 2014556711A JP 6092897 B2 JP6092897 B2 JP 6092897B2
- Authority
- JP
- Japan
- Prior art keywords
- pyrido
- pyrimidin
- methyl
- pyrazin
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(N(*(C([Rh])=**)=N*=*)N=C)=O Chemical compound CC(N(*(C([Rh])=**)=N*=*)N=C)=O 0.000 description 38
- GLUUGHFHXGJENI-UHFFFAOYSA-N C1NCCNC1 Chemical compound C1NCCNC1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ADBYGASBXODWTQ-IUCAKERBSA-N C[C@@H](CC(C[C@@H]1C)=O)N1C(OC(C)(C)C)=O Chemical compound C[C@@H](CC(C[C@@H]1C)=O)N1C(OC(C)(C)C)=O ADBYGASBXODWTQ-IUCAKERBSA-N 0.000 description 2
- WQYKURZEQHPVKO-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1(CC1)CCN1c(cn1)ccc1[N+]([O-])=O)=O Chemical compound CC(C)(C)OC(N(C1)CC1(CC1)CCN1c(cn1)ccc1[N+]([O-])=O)=O WQYKURZEQHPVKO-UHFFFAOYSA-N 0.000 description 1
- KSUHXIOQXPXRPF-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC1(CC1)CCN1c1ccc(N)nc1)=O Chemical compound CC(C)(C)OC(N(C1)CC1(CC1)CCN1c1ccc(N)nc1)=O KSUHXIOQXPXRPF-UHFFFAOYSA-N 0.000 description 1
- HWLNKJXLGQVMJH-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CC11CCNCC1)=O Chemical compound CC(C)(C)OC(N(C1)CC11CCNCC1)=O HWLNKJXLGQVMJH-UHFFFAOYSA-N 0.000 description 1
- WLELJCAXDLYHGS-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(C=CC1=NC(O)=C2)=NN1C2=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(C=CC1=NC(O)=C2)=NN1C2=O)=O WLELJCAXDLYHGS-UHFFFAOYSA-N 0.000 description 1
- VVIAILKBBFBIAD-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1C(C=CC1=NC(c2c[n](cc(C)nc3C)c3c2)=C2)=CN1C2=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1C(C=CC1=NC(c2c[n](cc(C)nc3C)c3c2)=C2)=CN1C2=O)=O VVIAILKBBFBIAD-UHFFFAOYSA-N 0.000 description 1
- MXVLKZHAGVQJCH-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCC1c1ccc(N)nn1)=O Chemical compound CC(C)(C)OC(N(CC1)CCC1c1ccc(N)nn1)=O MXVLKZHAGVQJCH-UHFFFAOYSA-N 0.000 description 1
- LTHHJBADUBFRDM-UHFFFAOYSA-N CC(C)(C)OC(NC(C1)C1(CC1)CN1C(C=CC1(C)NC(c2n[n](cc(C)nc3C)c3c2)=C2)=CN1C2=O)=O Chemical compound CC(C)(C)OC(NC(C1)C1(CC1)CN1C(C=CC1(C)NC(c2n[n](cc(C)nc3C)c3c2)=C2)=CN1C2=O)=O LTHHJBADUBFRDM-UHFFFAOYSA-N 0.000 description 1
- WIEJVMZWPIUWHO-MRVPVSSYSA-N CC(C)(C)OC(NC[C@H]1CNCC1)=O Chemical compound CC(C)(C)OC(NC[C@H]1CNCC1)=O WIEJVMZWPIUWHO-MRVPVSSYSA-N 0.000 description 1
- LVYOYMNCAWSORG-UHFFFAOYSA-N CC(C1)NC(C)CC1=O Chemical compound CC(C1)NC(C)CC1=O LVYOYMNCAWSORG-UHFFFAOYSA-N 0.000 description 1
- UWYWSYQRUMWQQT-UHFFFAOYSA-N CC(C[n]1c(C(C)=O)cc(Br)c1)=O Chemical compound CC(C[n]1c(C(C)=O)cc(Br)c1)=O UWYWSYQRUMWQQT-UHFFFAOYSA-N 0.000 description 1
- KVEMOSATIHPLAM-UHFFFAOYSA-N CC(c1cc(Br)c[nH]1)=O Chemical compound CC(c1cc(Br)c[nH]1)=O KVEMOSATIHPLAM-UHFFFAOYSA-N 0.000 description 1
- UAMYGGUINYQALX-GHRIWEEISA-N CC/C(/N1CCNCC1)=C\N(C(C)=NC(c1cnc2[nH]ccc2c1)=C1)C1=O Chemical compound CC/C(/N1CCNCC1)=C\N(C(C)=NC(c1cnc2[nH]ccc2c1)=C1)C1=O UAMYGGUINYQALX-GHRIWEEISA-N 0.000 description 1
- IPWKHHSGDUIRAH-UHFFFAOYSA-N CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C Chemical compound CC1(C)OB(B2OC(C)(C)C(C)(C)O2)OC1(C)C IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 1
- KBQYYDHZFPWMJO-UHFFFAOYSA-N CC1(C)OB(c2c[n](cc(C)nc3C)c3c2)OC1(C)C Chemical compound CC1(C)OB(c2c[n](cc(C)nc3C)c3c2)OC1(C)C KBQYYDHZFPWMJO-UHFFFAOYSA-N 0.000 description 1
- UOXAMYZTYZLSCC-UHFFFAOYSA-N CC1(C)OB(c2cnc3[nH]ccc3c2)OC1(C)C Chemical compound CC1(C)OB(c2cnc3[nH]ccc3c2)OC1(C)C UOXAMYZTYZLSCC-UHFFFAOYSA-N 0.000 description 1
- QYIVYSGMSBUWLE-UHFFFAOYSA-N CCOC(CC(c1n[n](cc(C)nc2C)c2c1)=O)=O Chemical compound CCOC(CC(c1n[n](cc(C)nc2C)c2c1)=O)=O QYIVYSGMSBUWLE-UHFFFAOYSA-N 0.000 description 1
- ZIVCTKWKGHVKMU-UHFFFAOYSA-N CCOC(CC(c1n[n](cc(C)nc2N(C)C)c2c1)=O)=O Chemical compound CCOC(CC(c1n[n](cc(C)nc2N(C)C)c2c1)=O)=O ZIVCTKWKGHVKMU-UHFFFAOYSA-N 0.000 description 1
- UFBGDLZUWIWIAT-UHFFFAOYSA-N CCOC(c1n[n](cc(C)nc2Cl)c2c1)=O Chemical compound CCOC(c1n[n](cc(C)nc2Cl)c2c1)=O UFBGDLZUWIWIAT-UHFFFAOYSA-N 0.000 description 1
- FCJFBUROMMKJRC-ZDUSSCGKSA-N C[C@@H](C1)NCCN1C(C=CC1=NC(c(cc2)cc3c2[s]c(C)n3)=C2)=CN1C2=O Chemical compound C[C@@H](C1)NCCN1C(C=CC1=NC(c(cc2)cc3c2[s]c(C)n3)=C2)=CN1C2=O FCJFBUROMMKJRC-ZDUSSCGKSA-N 0.000 description 1
- ADBYGASBXODWTQ-DTORHVGOSA-N C[C@H](CC(C[C@@H]1C)=O)N1C(OC(C)(C)C)=O Chemical compound C[C@H](CC(C[C@@H]1C)=O)N1C(OC(C)(C)C)=O ADBYGASBXODWTQ-DTORHVGOSA-N 0.000 description 1
- ALFBVTXTZONSGK-UHFFFAOYSA-N C[n](ccc1c2)c1ncc2C(N=C(C=C1)N2C=C1N1CCNCC1)=CC2=O Chemical compound C[n](ccc1c2)c1ncc2C(N=C(C=C1)N2C=C1N1CCNCC1)=CC2=O ALFBVTXTZONSGK-UHFFFAOYSA-N 0.000 description 1
- RKIFHYFCBVQODB-UHFFFAOYSA-N Cc(nc(C)c1c2)c[n]1nc2C(N=C(C=C1)N2C=C1N1CCC3(CNC3)CC1)=CC2=O Chemical compound Cc(nc(C)c1c2)c[n]1nc2C(N=C(C=C1)N2C=C1N1CCC3(CNC3)CC1)=CC2=O RKIFHYFCBVQODB-UHFFFAOYSA-N 0.000 description 1
- YMWCHDDTKRLLPB-HNNXBMFYSA-N Cc(nc(C)c1c2)c[n]1nc2C(N=C(C=C1)N2C=C1N1C[C@H](CN)CC1)=CC2=O Chemical compound Cc(nc(C)c1c2)c[n]1nc2C(N=C(C=C1)N2C=C1N1C[C@H](CN)CC1)=CC2=O YMWCHDDTKRLLPB-HNNXBMFYSA-N 0.000 description 1
- WUBXLHVAVIRTMV-UHFFFAOYSA-N Cc(nc(c1c2)N(C)C)c[n]1nc2C(N=C(C=C1)N2C=C1F)=CC2=O Chemical compound Cc(nc(c1c2)N(C)C)c[n]1nc2C(N=C(C=C1)N2C=C1F)=CC2=O WUBXLHVAVIRTMV-UHFFFAOYSA-N 0.000 description 1
- NAVSPWBTDOGOHB-UHFFFAOYSA-N Cc(nc(c1c2)N(C)C)c[n]1nc2C(N=C(C=C1)N2C=C1N1CCNCC1)=CC2=O Chemical compound Cc(nc(c1c2)N(C)C)c[n]1nc2C(N=C(C=C1)N2C=C1N1CCNCC1)=CC2=O NAVSPWBTDOGOHB-UHFFFAOYSA-N 0.000 description 1
- HRPYFTLAKXWCOZ-UHFFFAOYSA-N Cc(nc1C)c[n]2c1cc(C(N=C(C=C1)N3C=C1Cl)=CC3=O)c2 Chemical compound Cc(nc1C)c[n]2c1cc(C(N=C(C=C1)N3C=C1Cl)=CC3=O)c2 HRPYFTLAKXWCOZ-UHFFFAOYSA-N 0.000 description 1
- BXFOFQVWBPLDMU-UHFFFAOYSA-N Cc(nc1C)c[n]2c1cc([Br]=C)c2 Chemical compound Cc(nc1C)c[n]2c1cc([Br]=C)c2 BXFOFQVWBPLDMU-UHFFFAOYSA-N 0.000 description 1
- UKEZRMUJAZLDCS-UHFFFAOYSA-N Cc1c[n](cc(cc2C3C[IH]C3)C(N=C3N4N=C(C5CCN(CCO)CC5)C=C3)=CC4=O)c2n1 Chemical compound Cc1c[n](cc(cc2C3C[IH]C3)C(N=C3N4N=C(C5CCN(CCO)CC5)C=C3)=CC4=O)c2n1 UKEZRMUJAZLDCS-UHFFFAOYSA-N 0.000 description 1
- LPDZCBKKLWOOEZ-UHFFFAOYSA-N Cc1nc(ccc(C(N=C(C=C2)N3C=C2N2CCNCC2)=CC3=O)c2)c2[o]1 Chemical compound Cc1nc(ccc(C(N=C(C=C2)N3C=C2N2CCNCC2)=CC3=O)c2)c2[o]1 LPDZCBKKLWOOEZ-UHFFFAOYSA-N 0.000 description 1
- GBOHCVYEWUGNGI-UHFFFAOYSA-N Cc1nccc(C(C=CC2=NC(c(cc3)cc(OC)c3OC)=C3)=CN2C3=O)c1 Chemical compound Cc1nccc(C(C=CC2=NC(c(cc3)cc(OC)c3OC)=C3)=CN2C3=O)c1 GBOHCVYEWUGNGI-UHFFFAOYSA-N 0.000 description 1
- YJTXQLYMECWULH-UHFFFAOYSA-N Nc(nc1)ccc1F Chemical compound Nc(nc1)ccc1F YJTXQLYMECWULH-UHFFFAOYSA-N 0.000 description 1
- WYPCGKBOSFOHGU-UHFFFAOYSA-N O=C(CC(Oc(c(Cl)cc(Cl)c1)c1Cl)=O)Oc(c(Cl)cc(Cl)c1)c1Cl Chemical compound O=C(CC(Oc(c(Cl)cc(Cl)c1)c1Cl)=O)Oc(c(Cl)cc(Cl)c1)c1Cl WYPCGKBOSFOHGU-UHFFFAOYSA-N 0.000 description 1
- OWRPBSJLMYCZKL-UHFFFAOYSA-N O=C1N(C=C(C=C2)F)C2=NC(c2cnc3[nH]ccc3c2)=C1 Chemical compound O=C1N(C=C(C=C2)F)C2=NC(c2cnc3[nH]ccc3c2)=C1 OWRPBSJLMYCZKL-UHFFFAOYSA-N 0.000 description 1
- CGFYNRVHPARGFY-UHFFFAOYSA-N [O-][N+](c(nc1)ccc1F)=O Chemical compound [O-][N+](c(nc1)ccc1F)=O CGFYNRVHPARGFY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261597523P | 2012-02-10 | 2012-02-10 | |
| US61/597,523 | 2012-02-10 | ||
| PCT/US2013/025292 WO2013119916A2 (en) | 2012-02-10 | 2013-02-08 | Compounds for treating spinal muscular atrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017022640A Division JP6363744B2 (ja) | 2012-02-10 | 2017-02-09 | 脊髄性筋萎縮症を治療するための化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508075A JP2015508075A (ja) | 2015-03-16 |
| JP2015508075A5 JP2015508075A5 (https=) | 2016-03-03 |
| JP6092897B2 true JP6092897B2 (ja) | 2017-03-08 |
Family
ID=48948163
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014556711A Active JP6092897B2 (ja) | 2012-02-10 | 2013-02-08 | 脊髄性筋萎縮症を治療するための化合物 |
| JP2017022640A Active JP6363744B2 (ja) | 2012-02-10 | 2017-02-09 | 脊髄性筋萎縮症を治療するための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017022640A Active JP6363744B2 (ja) | 2012-02-10 | 2017-02-09 | 脊髄性筋萎縮症を治療するための化合物 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9586955B2 (https=) |
| EP (2) | EP2812004B1 (https=) |
| JP (2) | JP6092897B2 (https=) |
| KR (2) | KR102341596B1 (https=) |
| CN (3) | CN104349777B (https=) |
| AR (1) | AR092794A1 (https=) |
| AU (2) | AU2013216870B2 (https=) |
| BR (1) | BR112014019750B1 (https=) |
| CA (1) | CA2863874C (https=) |
| CL (1) | CL2014002100A1 (https=) |
| CO (1) | CO7061082A2 (https=) |
| CR (1) | CR20140376A (https=) |
| DK (1) | DK2812004T3 (https=) |
| EA (2) | EA037123B1 (https=) |
| EC (1) | ECSP14017269A (https=) |
| ES (1) | ES2697174T3 (https=) |
| HU (1) | HUE039779T2 (https=) |
| IL (2) | IL233959A (https=) |
| MA (1) | MA35920B1 (https=) |
| MX (2) | MX354074B (https=) |
| NZ (1) | NZ628186A (https=) |
| PE (1) | PE20142364A1 (https=) |
| PH (2) | PH12018501711B1 (https=) |
| PL (1) | PL2812004T3 (https=) |
| SG (2) | SG11201404713PA (https=) |
| TR (1) | TR201813877T4 (https=) |
| TW (2) | TWI629274B (https=) |
| UA (1) | UA116981C2 (https=) |
| WO (1) | WO2013119916A2 (https=) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10327940B2 (en) | 2008-11-09 | 2019-06-25 | 3D Systems, Inc. | Spiral brace |
| MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MX357834B (es) | 2012-01-26 | 2018-07-26 | Ptc Therapeutics Inc | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. |
| EP2812004B1 (en) * | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| CA2865957C (en) | 2012-03-01 | 2020-02-11 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| CA2868026C (en) | 2012-03-23 | 2021-02-16 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| CA2894992A1 (en) * | 2012-12-24 | 2014-07-03 | Ramot At Tel-Aviv University Ltd. | Agents for treating genetic diseases resulting from nonsense mutations, and methods for identifying the same |
| EP3035935B1 (en) | 2013-08-19 | 2020-03-11 | F. Hoffmann-La Roche AG | Compounds for use in the prophylaxis and treatment of cancer |
| US10195202B2 (en) | 2013-12-19 | 2019-02-05 | Ptc Therapeutics, Inc. | Methods for modulating the amount of RNA transcripts |
| ES2761423T3 (es) * | 2014-05-15 | 2020-05-19 | Hoffmann La Roche | Compuestos para tratar la atrofia muscular espinal |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| GB201410693D0 (en) | 2014-06-16 | 2014-07-30 | Univ Southampton | Splicing modulation |
| BR112017004056A2 (pt) | 2014-09-12 | 2017-12-05 | Biogen Ma Inc | composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo |
| CN107109411B (zh) | 2014-10-03 | 2022-07-01 | 冷泉港实验室 | 核基因输出的定向增加 |
| US10328060B2 (en) * | 2014-11-01 | 2019-06-25 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
| WO2016111896A1 (en) * | 2015-01-05 | 2016-07-14 | Sikorsky Aircraft Corporation | Integrated vibration damper for additively manufactured structure and method |
| CN107635999B (zh) | 2015-05-20 | 2020-09-25 | 豪夫迈·罗氏有限公司 | 用于治疗脊髓性肌萎缩的化合物 |
| US10668171B2 (en) * | 2015-05-30 | 2020-06-02 | Ptc Therapeutics, Inc. | Methods for modulating RNA splicing |
| EP3359685B1 (en) | 2015-10-09 | 2026-01-28 | University Of Southampton | Modulation of gene expression for deregulated protein expression |
| EA036399B1 (ru) | 2015-11-12 | 2020-11-06 | Ф. Хоффманн-Ля Рош Аг | Композиции для лечения спинальной мышечной атрофии |
| WO2017081111A1 (en) * | 2015-11-12 | 2017-05-18 | F. Hoffmann-La Roche Ag | Compounds for treating amyotrophic lateral sclerosis |
| SMT202000534T1 (it) | 2015-12-09 | 2020-11-10 | Cadent Therapeutics Inc | Modulatori eteroaromatici del recettore nmda e loro usi |
| EA201800367A1 (ru) | 2015-12-10 | 2019-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения болезни хантингтона |
| WO2017097728A1 (en) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Bridged piperidine derivatives |
| US11096956B2 (en) | 2015-12-14 | 2021-08-24 | Stoke Therapeutics, Inc. | Antisense oligomers and uses thereof |
| EP3933041B1 (en) | 2015-12-14 | 2024-01-31 | Cold Spring Harbor Laboratory | Antisense oligomers for treatment of autosomal dominant retardation |
| EP3448861B1 (en) | 2016-04-28 | 2021-04-21 | F. Hoffmann-La Roche AG | A process for the preparation of 2-pyrazolo[1,5-a]pyrazin-2-ylpyrido[1,2-a]pyrimidin-4-one |
| WO2017218884A1 (en) | 2016-06-16 | 2017-12-21 | Ionis Pharmaceuticals, Inc. | Combinations for the modulation of smn expression |
| JP2019535789A (ja) * | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| ES2975336T3 (es) | 2016-12-22 | 2024-07-04 | Novartis Ag | Moduladores del receptor NMDA y usos de los mismos |
| EP3634953B1 (en) | 2017-06-05 | 2024-01-03 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| JP2020523365A (ja) | 2017-06-14 | 2020-08-06 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを改変する方法 |
| MX2019015580A (es) * | 2017-06-28 | 2020-07-28 | Ptc Therapeutics Inc | Metodos para tratar la enfermedad de huntington. |
| CN111182898B (zh) * | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| JP7312749B2 (ja) | 2017-08-04 | 2023-07-21 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングをモジュレートする方法および組成物 |
| SG11202001590RA (en) | 2017-08-25 | 2020-03-30 | Stoke Therapeutics Inc | Antisense oligomers for treatment of conditions and diseases |
| SG11202002610TA (en) * | 2017-09-22 | 2020-04-29 | Hoffmann La Roche | Process for the prepration of 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one derivatives |
| GB2610100B (en) | 2017-10-23 | 2023-08-16 | Stoke Therapeutics Inc | Antisense oligomers for treatment of non-sense mediated RNA decay based conditions and diseases |
| EA202092001A1 (ru) | 2018-03-27 | 2021-01-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Соединения для лечения болезни гентингтона |
| US12060558B2 (en) | 2018-05-04 | 2024-08-13 | Stoke Therapeutics, Inc. | Methods and compositions for treatment of cholesteryl ester storage disease |
| WO2020005877A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| HRP20240935T1 (hr) | 2018-06-27 | 2024-11-22 | Ptc Therapeutics, Inc. | Heterociklični i heteroaril spojevi za liječenje huntingtonove bolesti |
| CN112469707B (zh) | 2018-06-27 | 2024-06-21 | 利伯纳生物科学株式会社 | 脊髓性肌萎缩症的预防剂或治疗剂 |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| BR112021001967A2 (pt) | 2018-08-03 | 2021-04-27 | Cadent Therapeutics, Inc. | moduladores de receptor nmda heteroaromáticos e usos dos mesmos |
| US20210355509A1 (en) * | 2018-08-07 | 2021-11-18 | The Children's Hospital Of Philadelphia | Alternative splicing regulation of gene expression and therapeutic methods |
| WO2020163405A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| JP7551629B2 (ja) | 2019-02-05 | 2024-09-17 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7603595B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| KR20210134003A (ko) | 2019-02-27 | 2021-11-08 | 스톡 테라퓨틱스, 인크. | 병태 및 질환의 치료를 위한 안티센스 올리고머 |
| JP7649257B2 (ja) | 2019-05-13 | 2025-03-19 | ピーティーシー セラピューティクス， インコーポレイテッド | ハンチントン病を処置するための化合物 |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| WO2021021775A1 (en) | 2019-07-31 | 2021-02-04 | Teva Pharmaceuticals International Gmbh | Solid state forms of risdiplam and process for preparation thereof |
| CN110540535B (zh) * | 2019-10-23 | 2020-07-31 | 上海再启生物技术有限公司 | 适合放大制备4-(6-氨基吡啶-3-基)取代哌啶的工艺方法 |
| CN111116576A (zh) * | 2019-12-01 | 2020-05-08 | 北京师范大学 | 一种喹嗪酮类化合物及其制备方法 |
| IL293340A (en) | 2019-12-02 | 2022-07-01 | Storm Therapeutics Ltd | Polyheterocyclic compounds as mettl3 inhibitors |
| JP2023512116A (ja) | 2020-01-28 | 2023-03-23 | プロテゴ バイオファーマ， インコーポレイテッド | トランスサイレチンの安定化及びトランスサイレチンの誤った折り畳みの阻害のための化合物、組成物、及び方法 |
| EP4103717A4 (en) * | 2020-02-12 | 2024-02-28 | The Children's Hospital of Philadelphia | COMPOSITIONS AND METHODS FOR INDUCIBLE ALTERNATIVE SPLICING REGULATION OF GENE EXPRESSION |
| WO2021174176A1 (en) | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Pyridazine dervatives for modulating nucleic acid splicing |
| MX2022010681A (es) | 2020-02-28 | 2023-03-21 | Remix Therapeutics Inc | Compuestos y metodos para modular el empalme. |
| WO2021174174A1 (en) | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Thiophenyl derivatives useful for modulating nucleic acid splicing |
| CN115485025A (zh) | 2020-02-28 | 2022-12-16 | 雷密克斯医疗公司 | 用于调节剪接的化合物和方法 |
| CR20220485A (es) | 2020-02-28 | 2022-11-10 | Ionis Pharmaceuticals Inc | Compuestos y métodos para modular smn2 |
| WO2021207530A1 (en) | 2020-04-08 | 2021-10-14 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| MX2022012678A (es) | 2020-04-08 | 2023-01-11 | Remix Therapeutics Inc | Compuestos y metodos para modular el corte y empalme. |
| BR112022022889A2 (pt) | 2020-05-11 | 2023-04-04 | Stoke Therapeutics Inc | Oligômeros antissentido de opa1 para tratamento de condições e doenças |
| TW202216710A (zh) | 2020-07-02 | 2022-05-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
| MX2023000167A (es) | 2020-07-02 | 2023-05-03 | Remix Therapeutics Inc | Derivados de 5-[5-(piperidin-4-il)tieno[3,2-c]pirazol-2-il]indazol y compuestos relacionados como moduladores para el corte y empalme de ácidos nucleicos y para el tratamiento de enfermedades proliferativas. |
| WO2022070071A1 (en) * | 2020-09-30 | 2022-04-07 | Janssen Biotech, Inc. | Dihydroorotate dehydrogenase inhibitors |
| MX2023010719A (es) | 2021-03-17 | 2023-09-20 | Hoffmann La Roche | Nuevos derivados de tiazolopirimidinona. |
| WO2023009585A2 (en) | 2021-07-28 | 2023-02-02 | Protego Biopharma, Inc. | Transthyretin stabilizing compounds |
| WO2023034812A1 (en) | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20240368163A1 (en) | 2021-08-30 | 2024-11-07 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| US20250333397A1 (en) | 2021-08-30 | 2025-10-30 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| CA3230256A1 (en) | 2021-08-30 | 2023-03-09 | Dominic Reynolds | Compounds and methods for modulating splicing |
| US20240400584A1 (en) | 2021-08-30 | 2024-12-05 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| TW202330552A (zh) | 2021-10-13 | 2023-08-01 | 美商雷密克斯醫療公司 | 調節剪接之化合物及方法 |
| IL312078A (en) * | 2021-10-13 | 2024-06-01 | Remix Therapeutics Inc | Compounds and methods for modulating nucleic acid splicing |
| WO2023133217A1 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| TW202346305A (zh) | 2022-01-05 | 2023-12-01 | 美商雷密克斯醫療公司 | 用於調節剪切之化合物及方法 |
| WO2023133229A2 (en) | 2022-01-05 | 2023-07-13 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2023240236A1 (en) | 2022-06-10 | 2023-12-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of spinal muscular atrophy related disorders |
| AU2024286618A1 (en) * | 2023-06-09 | 2025-10-30 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
| CN117263936B (zh) * | 2023-11-21 | 2024-02-23 | 中国中医科学院医学实验中心 | 一种咪唑并[1, 2-a]吡啶衍生物及其制备方法和在中枢神经系统渗透性HDAC6抑制药物中的应用 |
| WO2025233837A1 (en) | 2024-05-07 | 2025-11-13 | Takeda Pharmaceutical Company Limited | 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3558618A (en) * | 1968-04-01 | 1971-01-26 | Dow Chemical Co | Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones |
| US4122274A (en) * | 1977-05-25 | 1978-10-24 | Bristol-Myers Company | 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones |
| US4342870A (en) | 1980-03-28 | 1982-08-03 | Janssen Pharmaceutica N.V. | Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives |
| JPS56150091A (en) | 1980-03-28 | 1981-11-20 | Janssen Pharmaceutica Nv | 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture |
| US5089633A (en) | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US5726182A (en) * | 1990-05-02 | 1998-03-10 | Abbott Laboratories | Quinolizinone type compounds |
| AU4231293A (en) * | 1992-05-13 | 1993-12-13 | E.I. Du Pont De Nemours And Company | Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides |
| CA2222322A1 (en) | 1995-06-06 | 1996-12-12 | Abbott Laboratories | Quinolizinone type compounds |
| US5869500A (en) | 1996-12-13 | 1999-02-09 | Hoffmann-La Roche Inc. | Pyridone compounds useful in treating Alzheimer's disease |
| US6630488B1 (en) * | 1998-09-21 | 2003-10-07 | Biochem Pharma, Inc. | Quinolizinones as integrin inhibitors |
| AU7961100A (en) * | 1999-10-28 | 2001-05-08 | Daiichi Pharmaceutical Co., Ltd. | Drug discharge pump inhibitors |
| EP1857443B1 (en) * | 2000-01-24 | 2012-03-28 | AstraZeneca AB | Therapeutic morpholino-substituted compounds |
| JPWO2002087589A1 (ja) * | 2001-04-26 | 2004-08-12 | 第一製薬株式会社 | 薬剤排出ポンプ阻害薬 |
| DE60236322D1 (de) | 2001-12-07 | 2010-06-17 | Vertex Pharma | Verbindungen auf pyrimidin-basis als gsk-3-hemmer |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| AU2003256755A1 (en) | 2002-07-24 | 2004-02-09 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| WO2004113335A2 (en) | 2003-06-20 | 2004-12-29 | Chiron Corporation | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
| ATE373659T1 (de) | 2004-05-04 | 2007-10-15 | Warner Lambert Co | Pyrrolylsubstituierte pyrido(2,3-d)pyrimidin-7- one und derivate davon als therapeutische mittel |
| CA2595477A1 (en) | 2005-01-21 | 2006-07-27 | Janssen Pharmaceutica N.V. | Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8110681B2 (en) * | 2006-03-17 | 2012-02-07 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Compounds for the treatment of spinal muscular atrophy and other uses |
| WO2008013997A2 (en) | 2006-07-27 | 2008-01-31 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| WO2009151546A2 (en) * | 2008-05-27 | 2009-12-17 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| EP2138493A1 (en) * | 2008-06-26 | 2009-12-30 | Sanofi-Aventis | Substituted pyrimidone derivatives |
| US8932818B2 (en) | 2008-08-13 | 2015-01-13 | Ptc Therapeutics, Inc. | Screening assays for compounds that modulate programmed ribosomal frameshifting |
| WO2011050245A1 (en) * | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| EP2501231B1 (en) | 2009-11-20 | 2016-12-21 | Merck Sharp & Dohme Corp. | Quinolizidinone carboxamide m1 receptor positive allosteric modulators |
| CN102812023A (zh) * | 2010-01-13 | 2012-12-05 | 韩国巴斯德研究所 | 抗感染吡啶并(1,2-a)嘧啶类 |
| MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MX357834B (es) | 2012-01-26 | 2018-07-26 | Ptc Therapeutics Inc | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. |
| EP2812004B1 (en) * | 2012-02-10 | 2018-06-27 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| CA2865957C (en) | 2012-03-01 | 2020-02-11 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| CA2868026C (en) | 2012-03-23 | 2021-02-16 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| ES2761423T3 (es) | 2014-05-15 | 2020-05-19 | Hoffmann La Roche | Compuestos para tratar la atrofia muscular espinal |
| CN107635999B (zh) | 2015-05-20 | 2020-09-25 | 豪夫迈·罗氏有限公司 | 用于治疗脊髓性肌萎缩的化合物 |
-
2013
- 2013-02-08 EP EP13747100.9A patent/EP2812004B1/en active Active
- 2013-02-08 TR TR2018/13877T patent/TR201813877T4/tr unknown
- 2013-02-08 NZ NZ628186A patent/NZ628186A/en unknown
- 2013-02-08 PH PH1/2018/501711A patent/PH12018501711B1/en unknown
- 2013-02-08 JP JP2014556711A patent/JP6092897B2/ja active Active
- 2013-02-08 CN CN201380019368.6A patent/CN104349777B/zh active Active
- 2013-02-08 SG SG11201404713PA patent/SG11201404713PA/en unknown
- 2013-02-08 EP EP18179491.8A patent/EP3406252B1/en active Active
- 2013-02-08 EA EA201792465A patent/EA037123B1/ru unknown
- 2013-02-08 EA EA201491505A patent/EA029542B1/ru not_active IP Right Cessation
- 2013-02-08 PE PE2014001250A patent/PE20142364A1/es active IP Right Grant
- 2013-02-08 BR BR112014019750-4A patent/BR112014019750B1/pt active IP Right Grant
- 2013-02-08 UA UAA201409921A patent/UA116981C2/uk unknown
- 2013-02-08 CN CN201810234432.7A patent/CN108299314B/zh active Active
- 2013-02-08 KR KR1020207020788A patent/KR102341596B1/ko active Active
- 2013-02-08 WO PCT/US2013/025292 patent/WO2013119916A2/en not_active Ceased
- 2013-02-08 KR KR1020147025275A patent/KR102137087B1/ko active Active
- 2013-02-08 HU HUE13747100A patent/HUE039779T2/hu unknown
- 2013-02-08 SG SG10201609188WA patent/SG10201609188WA/en unknown
- 2013-02-08 CA CA2863874A patent/CA2863874C/en active Active
- 2013-02-08 ES ES13747100T patent/ES2697174T3/es active Active
- 2013-02-08 PL PL13747100T patent/PL2812004T3/pl unknown
- 2013-02-08 CN CN202411603136.1A patent/CN119528903A/zh active Pending
- 2013-02-08 MX MX2014009696A patent/MX354074B/es active IP Right Grant
- 2013-02-08 US US14/377,531 patent/US9586955B2/en active Active
- 2013-02-08 DK DK13747100.9T patent/DK2812004T3/en active
- 2013-02-08 AU AU2013216870A patent/AU2013216870B2/en active Active
- 2013-02-14 AR ARP130100450 patent/AR092794A1/es active IP Right Grant
- 2013-02-18 TW TW106106161A patent/TWI629274B/zh active
- 2013-02-18 TW TW102105672A patent/TWI585085B/zh active
-
2014
- 2014-08-05 IL IL233959A patent/IL233959A/en active IP Right Grant
- 2014-08-07 PH PH12014501786A patent/PH12014501786B1/en unknown
- 2014-08-08 CL CL2014002100A patent/CL2014002100A1/es unknown
- 2014-08-08 CR CR20140376A patent/CR20140376A/es unknown
- 2014-08-11 MX MX2022011699A patent/MX2022011699A/es unknown
- 2014-08-28 MA MA37313A patent/MA35920B1/fr unknown
- 2014-09-04 EC ECIEPI201417269A patent/ECSP14017269A/es unknown
- 2014-09-09 CO CO14198817A patent/CO7061082A2/es unknown
-
2016
- 2016-08-26 US US15/248,052 patent/US9879007B2/en active Active
-
2017
- 2017-02-09 JP JP2017022640A patent/JP6363744B2/ja active Active
- 2017-06-22 AU AU2017204248A patent/AU2017204248B2/en active Active
- 2017-08-17 IL IL254045A patent/IL254045B/en active IP Right Grant
- 2017-12-20 US US15/848,075 patent/US20180105526A1/en not_active Abandoned
-
2019
- 2019-08-15 US US16/541,401 patent/US10851101B2/en active Active
-
2020
- 2020-10-05 US US17/062,853 patent/US11753407B2/en active Active
-
2023
- 2023-07-26 US US18/359,209 patent/US20240067646A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6363744B2 (ja) | 脊髄性筋萎縮症を治療するための化合物 | |
| JP6193881B2 (ja) | 脊髄性筋萎縮症を治療するための化合物 | |
| CN104302181B (zh) | 用于治疗脊髓性肌萎缩的化合物 | |
| US9399649B2 (en) | Compounds for treating spinal muscular atrophy | |
| HK40005163A (en) | Compounds for treating spinal muscular atrophy | |
| HK40005163B (en) | Compounds for treating spinal muscular atrophy | |
| HK1202077B (en) | Compounds for treating spinal muscular atrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160108 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160108 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160810 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160830 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161130 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170110 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170209 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6092897 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |